Trial results for the BioSpy System, an investigational smart probe for lung lesion characterization, were posted on 2026-04-21. The study, involving 30 participants with Lung Cancer, evaluated the system's ability to differentiate lung lesions from healthy tissue, showing a mean ability of 80.9%.
Background
Lung cancer remains a leading cause of cancer-related mortality globally. Accurate and timely characterization of lung lesions is crucial for effective diagnosis, staging, and treatment planning. Current diagnostic methods often involve bronchoscopic biopsy, which can sometimes be limited by the ability to precisely differentiate between cancerous and healthy tissue in real-time. Technologies that can enhance this differentiation, such as impedance-based systems, hold potential to improve diagnostic accuracy and procedural efficiency.
Trial design
This completed study, designated as Phase NA, enrolled 30 participants with Lung Cancer. The objective was to evaluate the feasibility of the BioSpy System sensor to differentiate tissues encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses using impedance technology.
Key results
The trial reported several key measurements regarding the BioSpy System's performance:
- The Ability of BioSpy System to Acquire Electrophysiological Measurements in the Relevant Tissues During Bronchoscopic Biopsy:
- 26 participants in the Treatment Group successfully had electrophysiological measurements acquired.
- The Ability of BioSpy System to Differentiate the Lesion From Healthy Tissue:
- The mean ability was 80.9% (Standard Error 2.6%).
- Another measurement showed a mean ability of 88.5% (Standard Error 5.0%).
- A third measurement indicated a mean ability of 71.4% (Standard Error 8.5%).
- The Ability of BioSpy System to Differentiate Various Lesion Types:
- One measurement showed a mean ability of 78.7% (Standard Error 5.4%).
- Another measurement indicated a mean ability of 78.3% (Standard Error 9.7%).
- A third measurement showed a mean ability of 79.2% (Standard Error 8.6%).
What this means
The results suggest that the BioSpy System holds promise for improving the accuracy of tissue differentiation during bronchoscopic biopsies for lung cancer. The demonstrated ability to acquire electrophysiological measurements in relevant tissues and to differentiate lesions from healthy tissue, with mean percentages ranging from 71.4% to 88.5%, could provide clinicians with real-time feedback. This could potentially lead to more precise sampling, reduce the need for repeat procedures, and enhance diagnostic confidence, ultimately benefiting patients by facilitating earlier and more accurate treatment decisions.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06380361, titled "InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology", were posted on 2026-04-21 on clinicaltrials.gov.